Hansoh BioMedical R&D Company
39
22
23
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
2.6%
1 terminated/withdrawn out of 39 trials
50.0%
-36.5% vs industry average
21%
8 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (39)
A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
Role: lead
A Study of HS-20110 in Participants With Advanced Solid Tumors
Role: lead
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
Role: lead
A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
Role: lead
HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Role: lead
A Study of HS-20122 in Patients With Advanced Solid Tumors
Role: lead
Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors
Role: lead
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Role: lead
Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer
Role: lead
A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®)
Role: lead
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
Role: lead
Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
Role: lead
A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis
Role: lead
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
Role: lead
A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis
Role: lead
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
Role: lead
A Study of HS-20124 in Patients with Advanced Solid Tumors
Role: lead
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
Role: lead
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
Role: lead
A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
Role: lead